We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Test Aids Diagnosis of Preeclampsia

By LabMedica International staff writers
Posted on 09 Jan 2013
A test with high sensitivity and specificity level helps diagnosis of early onset preeclampsia.

The triage placental growth factor (PLGF) test is a fluorescence immunoassay, which, when used in conjunction with a Triage Meter enables the quantitative determination of PLGF in ethylenediaminetetraacetic acid (EDTA) anticoagulated plasma samples. More...
Together with other diagnostic and clinical information, the test aids in the diagnosis of preeclampsia.

The Alere (Linz, Austria) Triage PLGF test can provide a PLGF level from a maternal plasma specimen in just 15 minutes. The Triage MeterPro is a portable fluorescence instrument used to measure the results of the Triage tests from Alere. The Triage MeterPro can be used in a laboratory or in a point-of-care setting. It uses a Class 1 laser as a light source. Light from the laser hits a test device that has been inserted in the meter. This causes the fluorescent dye in the test device to give off energy. The more energy the fluorescent dye gives off, the stronger the signal.

The current criteria for defining preeclampsia (raised blood pressure and protein in urine) are nonspecific, appear late in the development of the disease, and result in over diagnosis because of their poor specificity.

On December 15, 2011, the Lancet published an editorial online that highlights the fact that many maternal deaths in the UK are associated with substandard care and are potentially preventable. The article suggests that it is the failure to diagnose or appropriately manage preeclampsia, which is the most common cause of maternal death.

Preeclampsia is a serious and potentially fatal condition that arises in pregnancy, usually in the second or third trimester. The exact cause is unknown but it is thought to be related to a problem with the placenta. The nonspecificity of signs and symptoms contribute to making clinical diagnosis a significant challenge, this represents a high risk to both mother and child.

Prof. Christopher Redman, emeritus professor of Obstetrics at John Radcliffe Hospital (Oxford, United Kingdom) commented, “A reliable and specific test that aids in the diagnosis of those aspects of the preeclampsia syndrome that jeopardize the safety of mother and/or unborn baby would be invaluable. Alere Triage PLGF is a major advance in the assessment for preterm disease.”

Related Links:
Alere
John Radcliffe Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Thyroid Test
Anti-Thyroid EIA Test
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.